Ashling Wahner

Associate Editor, OncLive

Ashling Wahner joined MJH Life Sciences in 2022. She produces OncLive's podcast, OncLive On Air, and helps ensure timely publication of news content and announcements from the FDA approval pipeline. She also attends conferences live and virtually to conduct video interviews and produce written coverage. Email: awahner@mjhlifesciences.com

Articles

Broader Testing Options Pave the Way for Increasingly Tailored Lung Cancer Treatments

May 17th 2022

The efficacy of targeted therapies for patients with lung cancer relies on detailed testing approaches found only in DNA- and RNA-based sequencing assays to identify specific mutations.

Sexual Harassment Rates Across Oncology Call for Improved Policies and Protections

May 12th 2022

Seventy percent of practicing oncologists had experienced sexual harassment by peers or superiors within 1 year, highlighting a substantial issue for both women and men, according to findings from a study that were published in the Journal of Clinical Oncology.

Cabozantinib Plus Nivolumab Shows Efficacy in Papillary Non–Clear Cell RCC

May 11th 2022

The combination of cabozantinib plus nivolumab demonstrated promising objective response rates in patients with non–clear cell renal cell carcinoma with prominent papillary features.

Tailored Treatment Improves Outcomes Across Lung Cancer

May 11th 2022

The hallmarks of lung cancer diagnosis and treatment are evolving, evidenced by increases in minimally invasive surgery, and immunotherapy combinations, as well as targeted therapies for rare molecular subsets.

Pembrolizumab Plus Chemoradiotherapy to Be Investigated as Bladder-Preservation Treatment in MIBC

May 10th 2022

Pembrolizumab plus concurrent chemoradiotherapy is being investigated as a potential therapy in patients with muscle-invasive bladder cancer.

Ibrutinib-Based Combination Therapy Displays Superior Efficacy Vs Monotherapy in MCL

May 9th 2022

Ibrutinib-based combination therapy demonstrated a higher overall response rate and longer progression-free survival compared with ibrutinib alone in patients with relapsed/refractory mantle cell lymphoma.

FDA-Approved CAR T-Cell Therapies Illuminate Advances in Multiple Myeloma

May 9th 2022

Noopur S. Raje, MD, discussed the presentation she gave at the 26th Annual International Congress on Hematologic Malignancies® on the CAR T-cell therapy product bb21217, other exciting myeloma treatments that were presented at ASH, and the need for increased treatment accessibility.

COVID-19 Mortality Rates Rise With Hospitalization and Rituximab Treatment in MCL

May 6th 2022

The overall mortality rate for patients with mantle cell lymphoma who contract COVID-19 is high, and mortality rates rise significantly in patients who are hospitalized or enter intensive care units, according to findings from a retrospective study that were published in Hemasphere.

Rituximab Plus Bendamustine Proves Promising in Young Patients With MCL

May 5th 2022

The combination of bendamustine and rituximab plus autologous stem cell transplantation and maintenance rituximab was shown to be an effective first-line treatment with comparable outcomes to R-CHOP/R-DHAP plus ASCT and observation in young patients with transplant-eligible mantle cell lymphoma.

The Future of Frontline CLL Treatment Hinges on Chemotherapy-Free Approaches

May 3rd 2022

Anthony Mato, MD, MSCE, discusses current data surrounding BTK inhibitors in chronic lymphocytic leukemia, the benefits of targeted therapies in this population, ways to begin addressing unmet needs, and the importance of improved clinical trial designs for varying patient populations.

Extended Follow-Up Confirms Survival Advantage of Adjuvant Capecitabine in Resected Biliary Tract Cancer

April 29th 2022

Adjuvant capecitabine continues to demonstrate an improvement in overall survival compared with observation following curative-intent resection in patients with biliary tract cancer.

Durvalumab Plus Oleclumab or Monalizumab Induces Increased Response Rates in NSCLC

April 28th 2022

Consolidation therapy with durvalumab and either oleclumab or monalizumab showed increased clinical benefits in patients with unresectable stage III non–small cell lung cancer.

Momelotinib Shows Promising JAK and ALK2 Inhibition in Myelofibrosis With Anemia

April 26th 2022

Srdan Verstovsek, MD, PhD, discusses the preliminary results of the MOMENTUM study and the potential for ALK2 inhibitor success in the larger anemia treatment landscape.

Administration of RP1 Through Intratumoral Injection Offers Unique Advantages in Melanoma Treatment

April 26th 2022

Oncolytic immunotherapy with talimogene laherparepvec and vusolimogene oderparepvec has the potential to provide unique clinical benefits in patients with melanoma through direct intratumoral administration.

Total Neoadjuvant Chemotherapy Generates Comparable Efficacy to Chemoradiotherapy in Locally Advanced Rectal Cancer

April 22nd 2022

Short-term radiotherapy followed by total neoadjuvant chemotherapy was found to be noninferior to long-term chemoradiotherapy in patients with locally advanced rectal cancer, according to findings from the phase 3 STELLAR study.

Eligibility Criteria of Pancreatic Cancer Trials Perpetuate Disparities in Black Patient Participation

April 21st 2022

Traditional eligibility criteria for pancreatic cancer clinical trials reinforce underrepresentation of racial and ethnic minorities in clinical trial candidacy and skew standards of care in favor of non-Hispanic White participants.

PROBE Trial in Progress to Understand Potential Benefits of Cytoreductive Nephrectomy in Metastatic RCC

April 20th 2022

Ulka Nitin Vaishampayan, MBBS, discusses the intent of the PROBE trial, as well as updates regarding the KEYNOTE-564 trial and novel agents in kidney cancer treatment.

Systemic Advances Shine, But Multidisciplinary Approaches Remain at Core of Skin Cancer Treatment

April 19th 2022

Jason Luke, MD, FACP, reviews key points from each presentation from an Institutional Perspectives in Cancer webinar on melanoma and provides perspective on the practice-changing benefits of therapies moving into earlier lines of treatment.

Frontline Therapy Advances Are Current Focus in SCLC and NSCLC

April 18th 2022

Lung cancer management methods are rapidly evolving to encompass immunotherapy in the frontline setting and approved second-line options with tyrosine kinase inhibitors and monoclonal antibodies in non–small cell lung cancer, as well as treatment advances in first- and second-line small cell lung cancer.

Lung Cancer Management Methods Expand to Encompass Multiple Treatment Perspectives

April 14th 2022

New treatment methods in patients with small cell lung cancer and non–small cell lung cancer are on the horizon, with the introduction of combination immunotherapy, biomarker assays, and supportive oncology programs for patients and care partners.